GB1463520A
(en)
*
|
1974-09-06 |
1977-02-02 |
Pfizer Ltd |
Process for the production of imidazolines
|
JPS5373571A
(en)
*
|
1976-12-10 |
1978-06-30 |
Otsuka Pharmaceut Co Ltd |
Carbostyril derivatives
|
US4188393A
(en)
|
1977-04-22 |
1980-02-12 |
Sandoz Ltd. |
Treating spastic conditions or relaxing muscles
|
US4145421A
(en)
|
1977-04-22 |
1979-03-20 |
Sandoz Ltd. |
Treating spastic conditions
|
FR2449087A2
(fr)
*
|
1979-02-16 |
1980-09-12 |
Rhone Poulenc Ind |
Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent
|
US4486432A
(en)
*
|
1982-09-30 |
1984-12-04 |
Eli Lilly And Company |
Quinoxalinedione leukotriene release inhibitors
|
FR2541680B1
(fr)
*
|
1983-02-24 |
1985-06-14 |
Rhone Poulenc Sante |
Nouveaux derives de l'amino-5 dithiole-1,2 one-3, leur preparation et les compositions medicinales qui les contiennent
|
JPS6118950U
(ja)
*
|
1984-07-10 |
1986-02-03 |
財団法人鉄道総合技術研究所 |
トロリ線の給油装置
|
JPS63296814A
(ja)
*
|
1987-05-29 |
1988-12-02 |
Ishigaki Kiko Kk |
集塵装置における濾材の目詰り除去装置
|
GB8827820D0
(en)
*
|
1988-11-29 |
1988-12-29 |
Janssen Pharmaceutica Nv |
(1h-azol-1-ylmethyl)substituted quinoline derivatives
|
US5180721A
(en)
*
|
1989-05-22 |
1993-01-19 |
Allergan, Inc. |
Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
|
US5281591A
(en)
*
|
1989-05-22 |
1994-01-25 |
Allergan, Inc. |
Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
|
US5077292A
(en)
*
|
1989-10-12 |
1991-12-31 |
Allergan, Inc. |
(2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
|
US5112822A
(en)
*
|
1989-10-12 |
1992-05-12 |
Allergan, Inc. |
(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
|
US5231096A
(en)
*
|
1989-10-12 |
1993-07-27 |
Allergan, Inc. |
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
|
US5198442A
(en)
*
|
1989-10-12 |
1993-03-30 |
Allergan, Inc. |
(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
|
US5204347A
(en)
*
|
1989-10-12 |
1993-04-20 |
Allergan, Inc. |
Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
|
US5326763A
(en)
*
|
1989-10-12 |
1994-07-05 |
Allergan, Inc. |
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
|
US5021416A
(en)
*
|
1989-10-31 |
1991-06-04 |
Allergan, Inc. |
Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
|
US5215991A
(en)
*
|
1990-01-26 |
1993-06-01 |
Allergan, Inc. |
Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
|
US5237072A
(en)
*
|
1990-02-06 |
1993-08-17 |
Allergan, Inc. |
Method for producing amino-2-imidazoline derivatives
|
US5130441A
(en)
*
|
1990-02-06 |
1992-07-14 |
Allergan, Inc. |
Method for producing amino-2-imidazoline derivatives
|
US5252595A
(en)
*
|
1990-02-28 |
1993-10-12 |
Allergan, Inc. |
Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
|
US5091528A
(en)
*
|
1990-09-12 |
1992-02-25 |
Allergan, Inc. |
6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
|
US6323204B1
(en)
*
|
1993-10-13 |
2001-11-27 |
Allergan |
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
|
DE69431880T2
(de)
*
|
1993-10-13 |
2003-09-18 |
Allergan Inc |
Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
|
US5580892A
(en)
*
|
1993-10-22 |
1996-12-03 |
Allergan |
Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
|
US5478858A
(en)
*
|
1993-12-17 |
1995-12-26 |
The Procter & Gamble Company |
5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
|
US5578607A
(en)
*
|
1993-12-17 |
1996-11-26 |
The Procter & Gamble Company |
6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
|
CN1137755A
(zh)
*
|
1993-12-17 |
1996-12-11 |
普罗克特和甘保尔公司 |
用作α-2肾上腺素能受体兴奋剂的6-(2-咪唑啉基氨基)喹喔啉化合物
|
DK0736020T3
(da)
*
|
1993-12-17 |
2000-08-07 |
Procter & Gamble |
6-(2-imidazolinylamino)quinolinforbindelser, der er egnede som alfa-2-adrenoceptoragonister
|
US5576437A
(en)
*
|
1993-12-17 |
1996-11-19 |
The Procter & Gamble Company |
7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
|
CN1046501C
(zh)
*
|
1994-02-08 |
1999-11-17 |
阿尔康实验室公司 |
新型硫脲复合物及制备硝基芳基亚氨基杂环的方法
|
WO1996004270A1
(fr)
|
1994-08-04 |
1996-02-15 |
Synaptic Pharmaceutical Corporation |
Nouveaux derives de benzimidazole
|
US6294563B1
(en)
|
1994-10-27 |
2001-09-25 |
Allergan Sales, Inc. |
Combinations of prostaglandins and brimonidine or derivatives thereof
|
US6194415B1
(en)
|
1995-06-28 |
2001-02-27 |
Allergan Sales, Inc. |
Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
|
US5916900A
(en)
|
1995-06-29 |
1999-06-29 |
The Procter & Gamble Company |
7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
|
TR199901885T2
(xx)
*
|
1996-11-25 |
1999-10-21 |
The Procter & Gamble Company |
Alfa-2 adrenosept�r agonistleri olarak yararl� 2-imidazolinilaminoindol bile�ikleri.
|
US6172095B1
(en)
|
1996-11-25 |
2001-01-09 |
The Procter & Gamble Company |
Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
|
US6306877B1
(en)
|
1999-08-09 |
2001-10-23 |
The Procter & Gamble Co. |
Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
|
AU5433898A
(en)
*
|
1996-11-25 |
1998-06-22 |
Procter & Gamble Company, The |
2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists
|
KR20000069131A
(ko)
|
1996-11-25 |
2000-11-25 |
데이비드 엠 모이어 |
알파-2 아드레날린수용체 아고니스트로서 유용한 구아니디닐 헤테로사이클 화합물
|
WO1998023611A1
(fr)
*
|
1996-11-25 |
1998-06-04 |
The Procter & Gamble Company |
COMPOSES 2-IMIDAZOLINYLAMINOBENZOXAZOLE CONVENANT COMME AGONISTES DE L'ADRENORECEPTEUR α-2
|
US6495583B1
(en)
|
1997-03-25 |
2002-12-17 |
Synaptic Pharmaceutical Corporation |
Benzimidazole derivatives
|
NZ504707A
(en)
|
1997-11-24 |
2002-11-26 |
Procter & Gamble |
5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
|
US6242442B1
(en)
|
1998-12-17 |
2001-06-05 |
Alcon Laboratories, Inc. |
Brinzolamide and brimonidine for treating ocular conditions
|
US8858961B2
(en)
|
2000-07-14 |
2014-10-14 |
Allergan, Inc. |
Compositions containing alpha-2-adrenergic agonist components
|
US20050026924A1
(en)
*
|
2000-07-14 |
2005-02-03 |
Allergan, Inc. |
Compositions containing alpha-2-adrenergic agonist components
|
JP4927298B2
(ja)
|
2000-07-14 |
2012-05-09 |
アラーガン、インコーポレイテッド |
α−2−アドレナリンアゴニスト成分を含有する組成物
|
US20040214829A1
(en)
*
|
2000-07-14 |
2004-10-28 |
Allergan, Inc. |
Compositions containing alpha-2-adrenergic agonist components
|
PL361027A1
(en)
*
|
2000-07-14 |
2004-09-20 |
Allergan,Inc. |
Compositions containing therapeutically active components having enhanced solubility
|
DE10161767A1
(de)
*
|
2001-12-15 |
2003-06-26 |
Merck Patent Gmbh |
2-Guanidino-4-heterocyclyl-chinazoline
|
US7642258B2
(en)
*
|
2002-04-19 |
2010-01-05 |
Allergan, Inc. |
Combination of brimonidine and timolol for topical ophthalmic use
|
US7030149B2
(en)
|
2002-04-19 |
2006-04-18 |
Allergan, Inc. |
Combination of brimonidine timolol for topical ophthalmic use
|
CA2501347A1
(fr)
*
|
2002-10-08 |
2004-04-22 |
Allergan, Inc. |
Methodes pour le traitement de la neurodegenerescence
|
BR0314541A
(pt)
*
|
2002-10-08 |
2005-07-26 |
Allergan Inc |
Tratamento de demência e doença de parkinson
|
US20040191332A1
(en)
*
|
2003-03-27 |
2004-09-30 |
Allergan, Inc. |
Preserved ophthalmic compositions
|
US8410102B2
(en)
|
2003-05-27 |
2013-04-02 |
Galderma Laboratories Inc. |
Methods and compositions for treating or preventing erythema
|
US7439241B2
(en)
|
2003-05-27 |
2008-10-21 |
Galderma Laboratories, Inc. |
Compounds, formulations, and methods for treating or preventing rosacea
|
EP2113246B1
(fr)
|
2003-08-07 |
2016-06-22 |
Allergan, Inc. |
Compositions d'administration d'agents therapeutiques dans les yeux et leurs methodes d'elaboration et d'utilisation
|
MXPA06001767A
(es)
*
|
2003-08-14 |
2006-05-12 |
Array Biopharma Inc |
Analogos de quinazolina como inhibidores de la tirosina quinasa receptora.
|
US7501427B2
(en)
|
2003-08-14 |
2009-03-10 |
Array Biopharma, Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
US20070042951A1
(en)
*
|
2003-10-08 |
2007-02-22 |
Allergan, Inc. |
Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
|
DK1761266T3
(da)
|
2004-05-25 |
2013-08-05 |
Galderma Pharma Sa |
Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
|
US7534795B2
(en)
*
|
2005-10-25 |
2009-05-19 |
Allergan, Inc. |
Compounds and their use related to compositions for treating disease
|
AU2006311577B2
(en)
|
2005-11-09 |
2013-02-07 |
Zalicus Inc. |
Methods, compositions, and kits for the treatment of medical conditions
|
CA2632194C
(fr)
|
2005-11-15 |
2012-01-03 |
Array Biopharma Inc. |
Inhibiteurs erbb
|
WO2008074068A1
(fr)
*
|
2006-12-20 |
2008-06-26 |
Prana Biotechnology Limited |
Dérivés de quinoline substitués utilisés comme agents non-amyloïdogéniques
|
US20080293728A1
(en)
*
|
2007-05-18 |
2008-11-27 |
Mcintire Gregory L |
Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions
|
US7842714B2
(en)
*
|
2008-03-03 |
2010-11-30 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating ocular pain
|
US9192571B2
(en)
*
|
2008-03-03 |
2015-11-24 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating or preventing ocular pain
|
WO2011044229A1
(fr)
|
2009-10-06 |
2011-04-14 |
Allergan, Inc. |
Dérivés de 2h-pyrrol-5-amine utilisés en tant que modulateurs des récepteurs alpha-adrénergiques
|
EP2329849B1
(fr)
|
2009-11-18 |
2015-04-29 |
Galderma Research & Development |
Combinaison d'un agoniste du récepteur alpha-2 adrénergique et d'un agent anti-inflammatoire non stéroïdien pour traiter ou empêcher un trouble cutané inflammatoire
|
US8394800B2
(en)
|
2009-11-19 |
2013-03-12 |
Galderma Laboratories, L.P. |
Method for treating psoriasis
|
US9522153B2
(en)
|
2009-12-22 |
2016-12-20 |
Allergan, Inc. |
Compositions and methods for lowering intraocular pressure
|
US8513247B2
(en)
|
2010-03-26 |
2013-08-20 |
Galderma Laboratories, L.P. |
Methods and compositions for safe and effective treatment of erythema
|
EP2552448B1
(fr)
|
2010-03-26 |
2019-04-24 |
Galderma Research & Development |
Compositions ameliorées avec de la brimonidine pour le traitement sûr et efficace de la télangiectasie
|
CN102883708A
(zh)
|
2010-04-07 |
2013-01-16 |
阿勒根公司 |
用于眼用组合物的防腐剂联合
|
CN102883709A
(zh)
|
2010-04-07 |
2013-01-16 |
阿勒根公司 |
用于眼用制剂的防腐组合物联合
|
AU2011282683B2
(en)
|
2010-07-29 |
2016-12-22 |
Allergan, Inc. |
Preservative free brimonidine and timolol solutions
|
SG189896A1
(en)
|
2010-10-21 |
2013-06-28 |
Galderma Sa |
Brimonidine gel compositions and methods of use
|
US8053427B1
(en)
|
2010-10-21 |
2011-11-08 |
Galderma R&D SNC |
Brimonidine gel composition
|
RU2014106364A
(ru)
|
2011-07-25 |
2015-08-27 |
Аллерган, Инк. |
Производные n-(имидазолидин-2-илидин)хинолина как модуляторы адренергических рецепторов альфа-2
|
GR1009419B
(el)
|
2017-11-07 |
2018-12-14 |
Φαρματεν Αβεε |
Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
|